Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Stem cell transplantation in primary systemic vasculitis].

Manfred Hensel1, Christoph Fiehn, Anthony D Ho

  • 1Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg. Manfred_Hensel@med.uni-heidelberg.de

Medizinische Klinik (Munich, Germany : 1983)
|January 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Blood advances·2026
Same author

Blood cell-derived transplants at 40.

Bone marrow transplantation·2026
Same author

Accumulation of Lymphoid Progenitors with Defective B Cell Differentiation and of Putative Natural Killer Progenitors in Aging Human Bone Marrow.

International journal of molecular sciences·2025
Same author

Prospective systematic classification of causes of death in the course of multiple myeloma.

Blood cancer journal·2025
Same author

One-Step Surface Functionalization of Hydrogel-Based, Stimulus-Responsive 3D Microstructures for Human Stem Cells.

ACS applied materials & interfaces·2025
Same author

[Rheumatoid Arthritis].

Deutsche medizinische Wochenschrift (1946)·2025
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

High-dose chemotherapy with autologous stem cell transplantation offers a life-saving alternative for patients with severe primary systemic vasculitis refractory to conventional treatments, achieving long-term remission.

Area of Science:

  • Immunology and Rheumatology
  • Hematology and Stem Cell Transplantation

Context:

  • Many autoimmune diseases, including primary systemic vasculitis (PSV), have limited treatment options, leading to organ damage and mortality.
  • Conventional immunosuppressive therapies often result in severe side effects, cumulative organ damage, and secondary malignancies.
  • A significant subgroup of PSV patients remains refractory to standard treatments, necessitating alternative therapeutic strategies.

Purpose:

  • To evaluate the efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation (HDCT) for patients with severe primary systemic vasculitis.
  • To explore HDCT as a potentially life-saving treatment for refractory PSV cases where conventional therapy fails.

Summary:

  • High-dose chemotherapy with autologous stem cell transplantation (HDCT) is explored as an alternative for patients with severe primary systemic vasculitis (PSV) unresponsive to conventional immunosuppression.

Related Experiment Videos

  • While standard therapies can induce remission, a subset of PSV patients requires long-term immunosuppression, facing disease progression or treatment toxicity, with a >20% 5-year mortality rate.
  • Single-center experience suggests HDCT can achieve long-term remissions in severe PSV patients refractory to conventional treatments, emphasizing careful patient selection and optimal timing.

    • Impact:

    • HDCT may offer a viable, potentially life-saving therapeutic option for severe, refractory primary systemic vasculitis.
    • Improved patient selection strategies and timing are crucial for optimizing HDCT outcomes in PSV.
    • This approach could reduce mortality and long-term morbidity associated with severe autoimmune diseases.